Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank23
Year-over-Year Change
Year-over-year operating cash flow growth rate
Latest
-49.69%
↓ 518% vs avg
Percentile
P23
Within normal range
Streak
2 qtr
Consecutive declineDecelerating
Average
11.89%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -49.69% |
| Q3 2025 | 111.48% |
| Q2 2025 | 229.93% |
| Q1 2025 | -24.99% |
| Q4 2024 | -316.58% |
| Q3 2024 | -64.80% |
| Q2 2024 | 252.31% |
| Q1 2024 | -173.59% |
| Q4 2023 | -108.29% |
| Q3 2023 | 709.32% |
| Q2 2023 | 64.57% |
| Q1 2023 | -26.14% |
| Q4 2022 | -14.48% |
| Q3 2022 | 6.14% |
| Q2 2022 | 28.26% |
| Q1 2022 | -14.02% |
| Q4 2021 | -12.02% |
| Q3 2021 | -10.00% |
| Q2 2021 | 48.29% |
| Q1 2021 | -91.37% |
| Q4 2020 | -11.62% |
| Q3 2020 | 18.48% |
| Q2 2020 | 45.02% |
| Q1 2020 | -25.61% |
| Q4 2019 | -7.31% |
| Q3 2019 | -163.26% |
| Q2 2019 | 253.15% |
| Q1 2019 | -25.29% |
| Q4 2018 | 2.18% |
| Q3 2018 | -49.78% |
| Q2 2018 | 34.03% |
| Q1 2018 | -51.07% |
| Q4 2017 | -4.76% |
| Q3 2017 | -21.36% |
| Q2 2017 | 19.22% |
| Q1 2017 | -28.07% |
| Q4 2016 | -3.71% |
| Q3 2016 | -7.59% |
| Q2 2016 | 16.05% |
| Q1 2016 | -57.59% |